Zobrazit v EDS

Glial activation among individuals with neurological post-acute sequelae of coronavirus disease 2019: A positron emission tomography study of brain fog using [18F]-FEPPA

Uloženo v:
Podrobná bibliografie
Název: Glial activation among individuals with neurological post-acute sequelae of coronavirus disease 2019: A positron emission tomography study of brain fog using [18F]-FEPPA
Autoři: Sean A.P. Clouston, Paul Vaska, Tesleem Babalola, John Gardus, III, Chuan Huang, Nicola Soriolo, Ashley Fontana, Christine DeLorenzo, Ramin Parsey, Benjamin J. Luft
Zdroj: Brain, Behavior, & Immunity - Health, Vol 44, Iss , Pp 100945- (2025)
Informace o vydavateli: Elsevier, 2025.
Rok vydání: 2025
Sbírka: LCC:Neurosciences. Biological psychiatry. Neuropsychiatry
Témata: Post-acute sequelae of COVID-19, Respiratory infection, Glial activation, Translocator protein, Essential Workers, Positron emission tomography, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Popis: Background: This study examined the regional distribution of glial activation in essential workers with neurological post-acute sequelae of coronavirus disease 2019 (COVID-19) infections (N-PASC). Methods: We injected ≤185 MBq of [18F]-FEPPA as an intravenous bolus and positron-emission tomography over 2 h. To measure distribution volume (VT) we recruited 24 essential workers (14 N-PASC, 10 Never-COVID-19 Controls, of whom 22 successfully placed arterial lines). Individuals with low binding affinity were excluded from this study, and VT was adjusted for translocator protein genotype. Analyses that passed the false discovery rate are reported. Results: Participants at midlife survived mild to moderate COVID-19 without hospitalization but reported onset of post-acute sequelae of COVID-19 (PASC) for, on average, 22 months before undergoing neuroimaging. Hippocampal VT was higher (VT = 1.70, 95% C.I. = [1.30–2.21], p = 0.001) in participants with persistent brain fog after COVID-19, reflecting an increase of 10.58 mL/cm3 in VT (area under the receiver-operating curve, AUC = 0.95 [0.85–1.00]). At a cutoff of 10.6, sensitivity/specificity/accuracy were 0.88/0.93/0.91. Conclusion: The results from this study imply that neuroimmune response is a distinct and identifiable characteristic of brain fog after COVID-19. Results suggest that [18F]-FEPPA could be used to support N-PASC diagnosis.
Druh dokumentu: article
Popis souboru: electronic resource
Jazyk: English
ISSN: 2666-3546
Relation: http://www.sciencedirect.com/science/article/pii/S2666354625000031; https://doaj.org/toc/2666-3546
DOI: 10.1016/j.bbih.2025.100945
Přístupová URL adresa: https://doaj.org/article/a2f653c9dcb64c30a99d3b23a4db25ea
Přístupové číslo: edsdoj.2f653c9dcb64c30a99d3b23a4db25ea
Databáze: Directory of Open Access Journals
Popis
Abstrakt:Background: This study examined the regional distribution of glial activation in essential workers with neurological post-acute sequelae of coronavirus disease 2019 (COVID-19) infections (N-PASC). Methods: We injected ≤185 MBq of [18F]-FEPPA as an intravenous bolus and positron-emission tomography over 2 h. To measure distribution volume (VT) we recruited 24 essential workers (14 N-PASC, 10 Never-COVID-19 Controls, of whom 22 successfully placed arterial lines). Individuals with low binding affinity were excluded from this study, and VT was adjusted for translocator protein genotype. Analyses that passed the false discovery rate are reported. Results: Participants at midlife survived mild to moderate COVID-19 without hospitalization but reported onset of post-acute sequelae of COVID-19 (PASC) for, on average, 22 months before undergoing neuroimaging. Hippocampal VT was higher (VT = 1.70, 95% C.I. = [1.30–2.21], p = 0.001) in participants with persistent brain fog after COVID-19, reflecting an increase of 10.58 mL/cm3 in VT (area under the receiver-operating curve, AUC = 0.95 [0.85–1.00]). At a cutoff of 10.6, sensitivity/specificity/accuracy were 0.88/0.93/0.91. Conclusion: The results from this study imply that neuroimmune response is a distinct and identifiable characteristic of brain fog after COVID-19. Results suggest that [18F]-FEPPA could be used to support N-PASC diagnosis.
ISSN:26663546
DOI:10.1016/j.bbih.2025.100945